In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect

Julien Andreani,Marion Le Bideau,Isabelle Duflot,Priscilla Jardot,Clara Rolland,Manon Boxberger,Nathalie Wurtz,Jean-Marc Rolain,Philippe Colson,Bernard La Scola,Didier Raoult
DOI: https://doi.org/10.1016/j.micpath.2020.104228
IF: 3.848
2020-08-01
Microbial Pathogenesis
Abstract:Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
immunology,microbiology
What problem does this paper attempt to address?